B

ack in May, Novartis scrambled to contain the fallout about its relationship with President Trump’s personal attorney, Michael Cohen, who was paid $1.2 million in consulting fees to provide access and insights into the new administration.

In carefully choreographed moments, the former chief executive, Joe Jimenez, took responsibility for the “mistake,” since he agreed to the one-year deal in early 2017. And his successor, Vas Narasimhan, who began running the company this past February, had already declined to renew the contract and vowed to uphold “ethical standards.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy